[Experience with the combined use of 1st- and 2d-group anti-arrhythmic preparations in patients with refractory arrhythmia].
Abdalla
A
A
Mazur
N A
NA
D000157:Aconitine / Q000031:analogs & derivatives*; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage; D008875:Middle Aged; D016293:Moricizine; D010640:Phenothiazines / Q000008:administration & dosage; D011433:Propranolol / Q000008:administration & dosage
D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D008801:Mexiletine; D016293:Moricizine; C051402:allapinin; D011433:Propranolol; D000157:Aconitine
Opyt kombinirovannogo primeneniia antiaritmicheskikh preparatov 1-ĭ i 2-ĭ gruppy u bol'nykh s refrakternoĭ aritmieĭ.